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1.1 Introduction
In the second Science and Technology Basic Plan,
life science was selected as one of the fields
having high priority. In the plan, regenerative
medicine was referred to as one of the areas in
which various challenges should be strategically
pursued with high priority in order to tackle
national and social problems. In addition, there
have been heated arguments about bioethical
issues arising in regenerative medicine and
regenerative therapy at the Council for Science
and Technology Policy, Cabinet Office, etc. In this
article, "regenerative medicine" is defined as a
term referring to both research and therapy
("regenerative therapy") with the use of
regenerated tissues.
1.2 Enlarged possibility of
applying regenerative
medicine
Various regenerative therapies have been
conducted so far, including transplantation of
regenerated skin and bone marrow as well as
transplantation of regenerated dopamine-
producing cells into the brains of patients with
Parkinson's disease. However, there is a crying
need for every type of tissue to be transplanted.
Use of stem cells is one of the solutions for this
problem. Stem cells are the cells that have the
ability both to self-replicate and to differentiate
into progenitor cells, which then differentiate or
develop into many different "mature" cell types
that have characteristic shapes and specialized
functions. Among the stem cells, somatic stem
cells, which are thought to have the ability to
differentiate into cells of specific tissues or organs,
as well as embryonic stem cells, which have the
ability to differentiate into any types of cells in
tissues and organs, are expected to create cells,
tissues or organs for transplantation and
contribute to health care in the future. Moreover,
possibility has been suggested that stem cells, in
combination with cloning technology, will be
applied to the creation of tailored organs for
transplantation not causing rejection reactions.
Among the two types of stem cells, embryonic
stem cells are harvested by extracting the inner
cell mass (a mass of cells that will develop into the
baby's tissues and organs) from the center of a
human embryo in the first week of life, resulting in
the destruction of the embryo. Therefore,
deliberate arguments have been made about the
bioethical aspects of the use of embryonic stem
cells for experimental or therapeutic purposes.
At first, as shown in Table 1, this article introduces;
i) the progress in research using somatic stem
cells and embryonic stem cells from the viewpoint
of regenerative medicine (Section 1.3). Then, from
the viewpoint of regenerative therapy, this article
describes; ii) the impact of regenerative therapy
on health care cost (Section 1.4); and iii)
significance of the establishment of foundations
Table 1: Contents of this feature report
Contents of this article
i) Progress in research using somatic stem cells and
embryonic stem cells (Section 1.3)
ii) Impact of regenerative therapy on health care cost
(Section 1.4)
iii) Significance of the establishment of foundations on
which to conduct regenerative therapy (Section 1.5)
iv) Bioethical issues concerning research using human
embryonic stem cells (Section 1.6)
v) Relationship between the knowledge possessed by
the people in the scientific community and the
knowledge which can be shared in society (Section 1.7)
on which to conduct regenerative therapy
(Section 1.5); followed by, iv) bioethical issues
concerning research using human embryonic
stem cells (Section 1.6); and finally, in Section 1.7,
v) the relationship between the "knowledge
possessed by the people in the scientific
community" and the "knowledge which can be
shared in society," which often has great
significance especially in studies in the field of
regenerative medicine.
1.3 Progress in research in the
field of regenerative medicine
Even in this postgenome era, no viable cells can be
artificially created from scratch. In any event,
some diseases require treatment using viable cells.
For example, even in this era of postgenome
research, blood transfusion and bone marrow
transplantation cannot be replaced by therapy
without using viable cells.
While the applicability of cell transplantation as
regenerative therapy for the treatment of
deficiency (loss) of cells or for tissue damage is
currently expanding, cells for use in such therapy
is desperately lacking. If intended cells can be
prepared in vitro, such shortage will be alleviated.
Under these circumstances, new findings and
technologies have come into the world, which
seem to promise to expand the applicability of
regenerated cell transplantation. Specifically
speaking, the following studies are being pursued.
1.3.1  Recent studies on somatic stem cells
(1) Studies aiming to develop therapeutic
methods for Parkinson's disease
Parkinson's disease is linked to the death of brain
cells that produce dopamine in the substantia
nigra. With the purpose of treating Parkinson's
disease, fetal brain cells have been transplanted to
affected patients to complement the function of
dead brain cells. However, because cells to be
transplanted should be collected from several
fetuses for the treatment of one patient, and
because it is technically difficult to extract specific
cells exclusively from brain tissues removed from
aborted fetuses, fetal brain cell transplantation has
not gained popularity as a therapy for Parkinson's
disease.
With this being the situation, many universities,
companies, etc., are exploring proteins (markers)
specifically expressed in progenitor cells for
dopamine-producing neurons, which can be
transplanted to Parkinson's disease patients for
therapeutic purposes, in murine models of
Parkinson's disease. It is expected that enough
dopamine-producing neurons to be infused to
Parkinson's disease patients for therapeutic
purposes will become harvestable if marker
proteins specific to such neurons are identified
and utilized.
(2) Studies targeting the recovery of
impaired neural functions
In a study using a rat model of spinal cord
(cervical cord) injury (associated with decreased
mobility of forelegs), a group led by Professor
Hideyuki Okano at Keio University transplanted
neural stem cells into the injured part of the spinal
cord, and observed that the cells differentiated
into neurons, etc., and that the neural network was
reconstructed, resulting in the recovery of the
mobility of the forelegs (Figure 1).
(3) Studies on plasticity of differentiated cells
It has been shown that hematopoietic stem cells
are capable of differentiating into neural, muscle
or liver stem cells, and that neural or muscle stem
cells have the ability to differentiate into
hematopoietic stem cells (Figure 2).
If intended cells become able to be prepared in
vitro by utilizing the plasticity of stem cells, i.e., by
reprogramming a specific kind of stem cells to
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Figure 1: Recovery of neural function after the
transplantation of somatic stem cells
become another kind of stem cells, somatic stem
cells are expected to have greater value in the
treatment of diseases.
1.3.2  Recent studies on embryonic stem cells
(1) Establishment of embryonic stem cell
lines
In 1998, the University of Wisconsin developed
the first human embryonic stem cell line with
monetary support from Geron Corp., which had a
great impact on regenerative therapy (Figure 3).
Studies on embryonic stem cells have been
conducted mainly on mice and Primates (Rhesus
monkeys and marmosets). The first embryonic
stem cell line was established in 1981, 1995 and
1998 for mice, Rhesus monkeys and marmosets,
respectively.
As mentioned above, the first human embryonic
stem cell line was established in 1998. To date, 64
lines of embryonic stem cells have been
established in the world (Table 2).
(3) Challenges to be addressed in studies
using embryonic stem cells
While it has been shown that embryonic stem
cells have pluripotency, i.e., capability to
differentiate into various kinds of cells in vitro
including nerve cells, muscle cells, blood cells and
insulin-secreting cells, the mechanism of
differentiation control remains under
investigation. The challenges to be addressed in
studies using embryonic stem cells include the
exploration of factors that induce the
differentiation of embryonic stem cells into cells
for intended functions, development of techniques
for extracting a specific kind of cells from a
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Figure 2: Plasticity of hematopoietic stem cells
Source: Authors' compilation by making reference to the
materials provided by Professor Nishikawa
Figure 3: Establishment of human embryonic stem cells
Source: Authors' compilation by making reference to a figure in
the June 2001 issue of the NIH report "Stem Cells."
Table 2: Number of established l ines of human
embryonic stem cells
Number of human embryonic stem cell lines reported to the
National Institutes of Health (NIH)
Source: Authors' compilation by making reference to the
materials provided by Professor Nishikawa
Goeteborg University (Sweden) 19
CyThera, Inc. (United States) 9
Reliance Life Sciences (India) 7
Monash University (Australia) 6
Karolinska Institute (Sweden) 5
Wisconsin Alumni Research Foundation 5
(United States)
BresaGen, Inc. (United States) 4
Technion-Israel Institute of Technology (Israel) 4
National Center for Biological Sciences (India) 3
University of California (United States) 2
Total 64
mixture of various kinds of differentiated cells, as
well as the development of technology for
inducing the efficacious proliferation of cells in
vitro.
With regard to the achievements in recent studies
on mouse embryonic stem cells, it has been
shown that a certain transcription factor (Oct-3/4)
is involved in the maintenance of undifferentiated
state of embryonic stem cells. In addition, a group
led by Professor Yoshiki Sasai at the Graduate
School of Medicine at Kyoto University has
developed a technique called the SDIA (stromal
cell-derived inducing activity) method and
succeeded in frequently inducing and culturing
the development of mouse embryonic stem cells
into dopamine-producing nerve cells in vitro,
which can be used to treat Parkinson's disease.
1.4 Impact of regenerative
therapy on health care cost
General concerns are rising that widespread
introduction of advanced medicine into clinical
practice including regenerative therapy might lead
to an increase in health care cost, but there are
some cases where introduction of regenerative
therapy does not seem to increase health care
cost.
Dr. Ron Mackay at the National Institutes of Health
(NIH) in the United States has developed a
technique for inducing the differentiation of
embryonic stem cells into pancreatic cells, which
could be successfully administered to diabetes
mellitus model mice to treat the disease (This
technique presents some problems in that the
process of differentiation of embryonic stem cells
into pancreatic cells cannot be completely
controlled, and requires further study).
Patients with type I diabetes mellitus, whose
pancreas (β -cells in the pancreas) cannot
synthesize or secrete insulin, develop the disease
at the age of less than 15 years old almost without
exception, and should receive the administration
of insulin throughout their lifetime after the onset
of the disease. If type I diabetes mellitus can be
completely treated with only a single shot of cells,
health care cost will be cut. As this example
illustrates, application of regenerative medicine to
actual clinical practice may not always result in an
increase in health care cost.
From this time forward, discussions will take place
in various quarters about the impact of the
introduction of regenerative therapy on health
care cost.
1.5 Significance of the
establishment of foundations 
on which to conduct
regenerative therapy
1.5.1  Pittsburgh in the United States as an
example
Pittsburgh is one of the cities that succeeded in
industrialization though the introduction of
regenerative medicine. About a half of the cases of
liver transplantation in the United States is
conducted in Pittsburgh. In Pittsburgh, health
care, education, etc., are provided under the
leadership of the organ transplantation centers,
and service industries have been actively
developed in a wide variety of fields including
organ transplantation (Table 3).
Factors which have contributed to the success of
Pittsburgh as a tissue engineering industry city
include; i) powerful motivation has been shared
among Pittsburgh citizens to resurrect the city's
faltering economy in the wake of the decline in
the steel industry as well as, ii) the city's
established intellectual infrastructure (For
example, Dr. Starzl, a world-renowned
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Table 3: Tissue engineering industry in Pittsburgh
Total value for regenerative
therapy-related companies in Pittsburgh
Number of related companies 26
Total market capitalization or valuation (estimated)* 4.3 billion dollars
Annual gross sales (estimated) 0.774 billion dollars
Source: Authors' compilation by making reference to the materials on the investigation conducted by the
Pittsburgh Tissue Engineering Initiative in 2000, http://www.pittsburgh-tissue.net/industry/
pdf/industry.pdf.
transplantation surgeon is a citizen of Pittsburgh,
and many Japanese transplantation surgeons have
visited him to receive training in transplantation
techniques).
1.5.2  Trends in Japan
—creation of foundations in the Osaka area
In Osaka and Kobe areas, there are universities,
institutions and companies that have first-rate
experts in the fields of research on physiologically
active substances, research in embryology,
research in regenerative medicine, transplantation
medicine, research on cloning, research on tissue
engineering, etc. Therefore, a project for health-
care industrialization of the areas, under the
initiative of Kobe City, has been proposed. This
project has been contracted out as one of the
district-oriented collaborative research projects
funded by the Japan Science and Technology
Corporation (JST), which is due to be completed
in 5 years starting from 2000, and is aiming to
build up comprehensive technological
foundations for research on, and application of,
regenerative medicine.
At present, collaborative efforts are being put forth
by the Institute of Biomedical Research and
Innovation (IBRI) of the Foundation for
Biomedical Research and Innovation, which holds
the core facility of the Kobe medical industry
development project, the Center for
Developmental Biology of the Institute of Physical
and Chemical Research, the Tissue Engineering
Center of the National Institute of Advanced
Industrial Science and Technology, the Institute for
Frontier Medical Sciences of Kyoto University, the
Exploratory Medical Center at the Kyoto
University Hospital, the Center for Future-oriented
Medicine of Osaka University, and other related
hospitals, etc. Under the current circumstances,
the challenge to be addressed from now on is to
let the collaboration system continue to function
efficiently.
In addition to the project mentioned above, efforts
shown in Table 4 are being made with the aim to
establish international foundations for research in
life science in the Osaka area.
1.6 Bioethical issues concerning
research using human
embryonic stem cells
As discussed, in countries with advanced medicine
including Japan, ardent expectations are placed on
the application of embryonic stem cells for health
care, while, deliberate arguments have been made
about the bioethical aspects of the use of
embryonic stem cells for experimental or
therapeutic purposes.
Because human embryonic stem cells are derived
from the inner cell mass removed from
blastocysts, which have developed from fertilized
embryos, early embryos are inevitably destroyed to
obtain human embryonic stem cells (Figure 3).
Therefore, some researchers feel that an early
human embryo intended to be destroyed to obtain
embryonic stem cells is a mere cluster of cells, but
other researchers believe that a human embryo
should be regarded as a human being at the time
of fertilization or at a certain stage of embryonic
development, and that harvesting of human
embryonic stem cells equals intentional
destruction of a human being (Figure 4).
The clue to addressing the bioethical problem is
given by the construction of an appropriate
decision-making system. For example, such
decision-making system can be built up by the
disclosure of detailed information by researchers
to the public as well as the provision of
opportunities for discussions by people with
different values agreeing to disagree, followed by
the formulation of fixed rules. Concerning the
disclosure of information by researchers to the
public, discussions are held in the following
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Table 4: Efforts aiming to establish international
foundations for research in life science in the
Osaka area
(1) Establishment of integrated foundations in the
northern area of Osaka and the Kobe area.
Enhancement of the functions as foundations for
research, intensive enforcement of measures to
support industrialization, etc.
(2) Facilitation of cooperation among integrated
foundations for research in life science under the
initiative of the Osaka and Kobe areas.
Development of a system to promote research though
collaboration among government, academia and
industry, and construction of high-capacity, high-speed
information networks, etc.
(3) Provision of opportunities for deliberation by the
authorities concerned, etc., to intensively facilitate
comprehensive support.
chapter.
The first public discussion about ethical issues
concerning research using human embryonic
stem cells was held at the Human Embryo
Research Subcommittee meeting under the
Bioethics Committee of the Scientific Council.
During the discussion, opinions were exchanged
about bioethical aspects of studies using human
embryos, mainly human embryonic stem cells, and
the "Ethical Principles of Research on Human
Embryos, Mainly Human Embryonic Stem Cells "
were formulated.
Under the principles, it is specified that
establishment of human embryonic stem cell lines
should be conducted with great care, and can be
performed only within a strictly constructed
conceptual framework in consideration of both
the benefit of research using human embryonic
stem cells and the problems associated with the
harvest of those cells, i.e., destruction of the early
embryo as early human life. With regard to the use
of established embryonic stem cell lines, it is
specified that a conceptual framework should be
developed because uncontrolled use could lead to
the indiscriminate use of human embryonic stem
cells, accelerate the destruction of human
embryos in vain, and give rise to ethical issues
derived from the pluripotency (capability to
differentiate any kinds of cells) of such cells.
Concerning the clinical study using human
embryonic stem cells, it is specified that due
consideration should be taken in terms of safety of
clinical practices with the use of such cells, and
that clinical studies on the introduction of human
embryonic stem cells, or cells or tissue
differentiated from such cells into an individual
human body, should not be conducted until
guidelines on clinical application of embryonic
stem cells are developed.
In response to the formulation of the "Ethical
Principles of Research on Human Embryos, Mainly
Human Embryonic Stem Cells," the Ministry of
Education, Culture, Sports, Science and Technology
prepared the draft of the "Guidelines for the
Establishment and Use of Human Embryonic Stem
Cells" and invited comments about the guidelines
from the public. Thereafter, the Ministry sought
the advice of experts participating in the Council
for Science and Technology Policy, Cabinet Office,
about the draft guidelines in September 25, 2001.
Then, following repeated discussions held under
the leadership of the Bioethics Review Panel of
Experts, which is a subordinate organization of the
council, a report on the opinions of experts was
submitted to the Ministry of Education, Culture,
Sports, Science and Technology.
In this context, the "Guidelines for the
Establishment and Use of Human Embryonic Stem
Cells" was put into effect by the Ministry of
Education, Culture, Sports, Science and Technology
in September 25, 2001. These guidelines specify
that human embryonic stem cells shall be handled
with integrity and care lest the sanctity of human
life should be violated. In addition, the guidelines
provide that the establishment and use of
embryonic stem cell lines shall be restricted to
basic research for the time being (Article 2,
Section 2). Furthermore, it is also stipulated in the
guidelines that practical application of human
embryonic stem cells such as the manufacturing
of pharmaceutical products derived from such
cells for use in clinical practice as well as the
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Figure 4: How should the human embryo be interpreted?
Source: Authors' compilation by making reference to the materials provided by Professor Nishikawa
massive supply of such cells to be used in drug
toxicity tests, shall not be conducted for the
present time.
Table 5 provides a summary of moves to address
bioethical issues about the establishment and use
of human embryonic stem cells in major
industrialized nations.
1.7 Conclusion
To date, scientists have provided the general
public with knowledge derived from scientific
evidences they acquired in their research
activities. In other words, scientists have
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Table 5: Moves to address bioethical issues about the establishment and use of human embryonic stem cells in major
industrialized nations
Country name Date Moves to address bioethical issues
about the establishment and use of human embryonic stem cell lines
Japan September 2001 According to the "Guidelines for the Establishment and Use of Human Embryonic Stem
Cells," the establishment and use should be restricted to basic research for the time being.
Germany 1990 Under the Embryo Protection Law, people are absolutely prohibited from conducting any
research using human embryonic stem cells.
United Kingdom January 2001 Under the Human Fertilisation and Embryology Act, people are allowed to establish human
embryonic stem cell lines from cloned human embryos.
United States August 2001 Under an executive order, public monetary support may be provided to studies using
human embryonic stem cells, but establishment of a new human embryonic stem cell line is
prohibited.
France ——— Under the Bioethics Law, research on human embryonic stem cells excluding observations
of such cells is prohibited.
An amendment to the Bioethics Law is planned to be submitted to allow scientists to
establish human embryonic stem cell lines from spare embryos.
Figure 5: Process of the development of knowledge possessed by the scientific community
into that shared among the public
conferred a benefit on society in that they have
provided information that can be accepted as
"reliable knowledge" by the general public, which
will eventually bring profit to society by way of
practical application.
Future challenges to be confronted by scientists,
particularly in researches in the field of
regenerative medicine, are to; build up and
accumulate knowledge that can be shared among
the general public, disclose information
(knowledge) derived from their studies with high
transparency, and communicate with the general
public, which may have various opinions and may
favor or oppose a certain subject in question or
take a fence-straddling position (Figure 5).
In addition, it is desirable that institutions be
established from which information digested into
a more easy-to-understand form is continuously
disseminated among the general public (Figure 6)
(For example, at the Center for Developmental
Biology [CDB] of the Institute of Physical and
Chemical Research, discussions have been held by
the Institutional Review Board (IRB) not only
about various bioethical issues but also about how
information obtained in research activities at the
institute should be disclosed from the viewpoint
of outsiders).
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(Original Japanese version: published in November 2001)
Figure 6: Requirements for the promotion of the development of knowledge within scientific circles into
that shared among the public
Candid disclosure of information is required from experts in the field of life science
1. Sense of responsibility as, and candid disclosure of information by, scientists.
•  Establishment of the system of on-site observation tours to laboratories intended for people
in the mass media, economic world and judicial world.
•  Improvement in communication between the scientific community and society.
2. Establishment of institutions as providers of life science-related information, which are
accessible to everyone.
Source: Authors' compilation by making reference to the materials provided by Professor Nishikawa
